Anakinra as first‐line disease‐modifying therapy in systemic juvenile idiopathic arthritis: Report of forty‐six patients from an international multicenter series
Top Cited Papers
- 28 January 2011
- journal article
- clinical trial
- Published by Wiley in Arthritis & Rheumatism
- Vol. 63 (2), 545-555
- https://doi.org/10.1002/art.30128
Abstract
Objective To examine the safety and efficacy of the interleukin‐1 (IL‐1) receptor antagonist anakinra as first‐line therapy for systemic juvenile idiopathic arthritis (JIA). Methods Patients with systemic JIA receiving anakinra as part of initial disease‐modifying antirheumatic drug (DMARD) therapy were identified from 11 centers in 4 countries. Medical records were abstracted using a standardized instrument, and resulting data were analyzed to characterize concomitant therapies, clinical course, adverse events, and predictors of outcome. Results Among 46 patients meeting inclusion criteria, anakinra monotherapy was used in 10 patients (22%), while 67% received corticosteroids and 33% received additional DMARDs. Outcomes were evaluated at a median followup interval of 14.5 months. Fever and rash resolved within 1 month in >95% of patients, while C‐reactive protein and ferritin normalized within this interval in >80% of patients. Active arthritis persisted at 1 month in 39% of patients, at 3 months in 27%, and at >6 months of followup in 11%. Approximately 60% of patients, including 8 of 10 receiving anakinra monotherapy, attained a complete response without escalation of therapy. Disease characteristics and treatment were similar in partial and complete responders, except that partial responders were markedly younger at onset (median age 5.2 years versus 10.2 years; P = 0.004). Associated adverse events included documented bacterial infection in 2 patients and hepatitis in 1 patient. Tachyphylaxis was not observed. Conclusion Anakinra as first‐line therapy for systemic JIA was associated with rapid resolution of systemic symptoms and prevention of refractory arthritis in almost 90% of patients during the interval examined. These results justify further study of IL‐1 inhibition as first‐line, rather than rescue, therapy in systemic JIA.Keywords
This publication has 31 references indexed in Scilit:
- Early outcomes and improvement of patients with juvenile idiopathic arthritis enrolled in a Canadian multicenter inception cohortArthritis Care & Research, 2010
- Acute hepatitis in three patients with systemic juvenile idiopathic arthritis taking interleukin-1 receptor antagonistPediatric Rheumatology, 2009
- Anakinra for Systemic Juvenile ArthritisJCR: Journal of Clinical Rheumatology, 2009
- Persistent Elevation of Fibrin D-Dimer Predicts Longterm Outcome in Systemic Juvenile Idiopathic ArthritisThe Journal of Rheumatology, 2009
- Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritisArthritis Research & Therapy, 2009
- Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter studyClinical Rheumatology, 2008
- Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trialsAnnals Of The Rheumatic Diseases, 2008
- Predictors of disease course and remission in systemic juvenile idiopathic arthritis: Significance of early clinical and laboratory featuresArthritis & Rheumatism, 2006
- Preliminary definition of improvement in juvenile arthritisArthritis & Rheumatism, 1997
- Prognostic indicators of joint destruction in systemic-onset juvenile rheumatoid arthritisThe Journal of Pediatrics, 1992